DE10299042I1 - Verwendung von tetrahydrocarbazolderivaten als 5ht1-Rezeptoragonisten - Google Patents

Verwendung von tetrahydrocarbazolderivaten als 5ht1-Rezeptoragonisten

Info

Publication number
DE10299042I1
DE10299042I1 DE2002199042 DE10299042C DE10299042I1 DE 10299042 I1 DE10299042 I1 DE 10299042I1 DE 2002199042 DE2002199042 DE 2002199042 DE 10299042 C DE10299042 C DE 10299042C DE 10299042 I1 DE10299042 I1 DE 10299042I1
Authority
DE
Germany
Prior art keywords
receptor agonists
tetrahydrocarbazole derivatives
tetrahydrocarbazole
derivatives
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE2002199042
Other languages
English (en)
Other versions
DE10299042I2 (de
Inventor
Francis David King
Laramie Mary Gaster
Alberto Julio Kaumann
Rodney Christopher Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ligand UK Ltd
Original Assignee
Vernalis PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10697363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10299042(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vernalis PLC filed Critical Vernalis PLC
Application granted granted Critical
Publication of DE10299042I1 publication Critical patent/DE10299042I1/de
Publication of DE10299042I2 publication Critical patent/DE10299042I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE2002199042 1991-06-26 1992-06-17 Verwendung von Tetrahydrocarbazolderivaten als 5HT1-Rezeptor-agonisten. Active DE10299042I2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919113802A GB9113802D0 (en) 1991-06-26 1991-06-26 Medicaments
PCT/GB1992/001082 WO1993000086A1 (en) 1991-06-26 1992-06-17 Use of tetrahydrocarbazone derivatives as 5ht1 receptor agonists

Publications (2)

Publication Number Publication Date
DE10299042I1 true DE10299042I1 (de) 2003-02-20
DE10299042I2 DE10299042I2 (de) 2005-02-03

Family

ID=10697363

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69226953T Expired - Lifetime DE69226953T2 (de) 1991-06-26 1992-06-17 Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten
DE2002199042 Active DE10299042I2 (de) 1991-06-26 1992-06-17 Verwendung von Tetrahydrocarbazolderivaten als 5HT1-Rezeptor-agonisten.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69226953T Expired - Lifetime DE69226953T2 (de) 1991-06-26 1992-06-17 Verwendung von tetrahydrocarbazolderivaten als 5ht1-rezeptor-agonisten

Country Status (35)

Country Link
US (2) US5464864A (de)
EP (1) EP0591280B1 (de)
JP (1) JP3261502B2 (de)
KR (1) KR100251571B1 (de)
CN (1) CN1034072C (de)
AP (1) AP344A (de)
AT (1) ATE170746T1 (de)
BR (2) BR9206237A (de)
CA (1) CA2113726C (de)
CZ (3) CZ282327B6 (de)
DE (2) DE69226953T2 (de)
DK (1) DK0591280T3 (de)
FI (1) FI103967B (de)
GB (1) GB9113802D0 (de)
HK (1) HK1014669A1 (de)
HU (1) HU218907B (de)
IE (1) IE922062A1 (de)
IL (4) IL117104A (de)
LU (1) LU90939I2 (de)
MA (1) MA22563A1 (de)
MX (1) MX9203444A (de)
NL (1) NL300103I2 (de)
NO (2) NO304774B1 (de)
NZ (1) NZ243288A (de)
PL (3) PL169392B1 (de)
PT (1) PT100620B (de)
RU (1) RU2137474C1 (de)
SA (1) SA92130141B1 (de)
SG (1) SG47877A1 (de)
SI (1) SI9200125B (de)
SK (3) SK280905B6 (de)
TW (1) TW214544B (de)
UA (1) UA41254C2 (de)
WO (1) WO1993000086A1 (de)
ZA (1) ZA924658B (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
GB9226566D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
GB9226530D0 (en) * 1992-12-21 1993-02-17 Smithkline Beecham Plc Compounds
US5618948A (en) * 1995-05-26 1997-04-08 Smithkline Beecham P.L.C. Process for preparing an enantiomer of a carbazole derivative
DE69610793T2 (de) * 1995-06-23 2001-05-03 Lilly Co Eli 6-Subsitituierte-1,2,3,4-tetrahydro-9H-Carbazole und 7-substituierte-1OH-Cyclohepta(7,6-B)-Indole
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6066092A (en) * 1997-11-06 2000-05-23 Cady; Roger K. Preemptive prophylaxis of migraine device and method
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
CN1662538A (zh) 2002-06-21 2005-08-31 苏文生命科学有限公司 可作为治疗剂的对血清素受体具有亲和力的芳烷基吲哚、其制备工艺及其含有该物质的药物组合物
MXPA04012832A (es) 2002-06-21 2005-05-27 Suven Life Sciences Ltd Arilsulfonil indoles novedosos que tienen afinidad por el receptor de la serotonina, utiles como agentes terapeuticos, proceso para su preparacion y composiciones farmaceuticas que los contienen.
CA2509982C (en) 2002-11-28 2011-11-08 Suven Life Sciences Limited N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them
AU2003285759B2 (en) 2002-11-28 2010-01-28 Suven Life Sciences Limited N-arylsulfonyl-3-aminoalkoxyindoles
NZ540841A (en) 2002-12-18 2008-08-29 Suven Life Sciences Ltd Tetracyclic 3-substituted indoles having serotonin receptor affinity
NZ574705A (en) * 2006-08-07 2011-12-22 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
EP2813144A1 (de) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgetische Zusammensetzungen enthaltend ein Antihistamin
US8148377B2 (en) 2007-02-11 2012-04-03 Map Pharmaceuticals, Inc. Method of therapeutic administration of DHE to enable rapid relief of migraine while minimizing side effect profile
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
EP2451274B1 (de) 2009-07-08 2017-10-04 Charleston Laboratories, Inc. Pharmazeutische zusammensetzungen
US10098674B2 (en) 2009-10-22 2018-10-16 Nuvasive, Inc. System and method for posterior cervical fusion
WO2011050140A1 (en) 2009-10-22 2011-04-28 Blue Fury Consulting, L.L.C. Posterior cervical fusion system and techniques
US9399053B2 (en) 2011-07-22 2016-07-26 The University Of Chicago Treatments for migraine and related disorders
AU2013361337A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. 8'-Hydroxy-Dihydroergotamine compounds and compositions
EP2816030A1 (de) 2013-06-20 2014-12-24 Duke Chem, S. A. Verfahren zur Herstellung von Frovatriptan und dessen Enantiomer
GB201312768D0 (en) 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
WO2017152130A1 (en) 2016-03-04 2017-09-08 Charleston Laboratories, Inc. Pharmaceutical compositions
EP3766483A1 (de) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispergierbare pulverzusammensetzung mit einem triptan

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642816A (en) * 1967-08-10 1972-02-15 Sterling Drug Inc 3-acetamido-1 2 3 4-tetrahydrocarbazole
US3959309A (en) * 1968-01-24 1976-05-25 Sterling Drug Inc. 3-Amido-1,2,3,4-tetrahydrocarbazoles
US4062864A (en) * 1968-01-24 1977-12-13 Sterling Drug Inc. 3-Hydroxy carbazole derivatives
US3592824A (en) * 1970-03-12 1971-07-13 Miles Lab 3-substituted amino-1,2,3,4-tetrahydrocarbazoles
US4172834A (en) * 1971-08-16 1979-10-30 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
BE787537A (fr) * 1971-08-16 1973-02-14 Sterling Drug Inc Tetrahydrocarbazoles
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
US4254134A (en) * 1978-03-17 1981-03-03 Endo Laboratories, Inc. Antidepressant 2-amino- and -2-(substituted amino)-cis-hexahydro-carbazoles
EP0115607A1 (de) * 1983-01-04 1984-08-15 MERCK PATENT GmbH Tetrahydrocarbazolderivate

Also Published As

Publication number Publication date
ZA924658B (en) 1993-12-24
PT100620A (pt) 1993-09-30
WO1993000086A1 (en) 1993-01-07
KR100251571B1 (ko) 2000-07-01
NL300103I2 (nl) 2003-02-03
FI103967B1 (fi) 1999-10-29
MX9203444A (es) 1993-12-01
FI935842A0 (fi) 1993-12-23
CA2113726C (en) 2008-02-19
NL300103I1 (nl) 2002-12-02
IL117104A (en) 1997-09-30
SA92130141B1 (ar) 2005-12-18
SI9200125A (en) 1992-12-31
DE69226953D1 (de) 1998-10-15
NO934800D0 (no) 1993-12-23
CZ282061B6 (cs) 1997-05-14
IL117104A0 (en) 1996-06-18
TW214544B (de) 1993-10-11
CZ150696A3 (en) 1997-06-11
CZ286193A3 (en) 1994-07-13
IL117105A0 (en) 1996-06-18
IE922062A1 (en) 1992-12-30
CA2113726A1 (en) 1993-01-07
RU2137474C1 (ru) 1999-09-20
PL169410B1 (pl) 1996-07-31
DE10299042I2 (de) 2005-02-03
CN1069726A (zh) 1993-03-10
SK280905B6 (sk) 2000-09-12
HK1014669A1 (en) 1999-09-30
PL171034B1 (en) 1997-02-28
IL102322A (en) 1997-09-30
SI9200125B (en) 2001-12-31
NO2005011I1 (no) 2005-05-18
US5464864A (en) 1995-11-07
GB9113802D0 (en) 1991-08-14
CZ282327B6 (cs) 1997-06-11
FI103967B (fi) 1999-10-29
CN1034072C (zh) 1997-02-19
NO2005011I2 (no) 2008-02-11
IL117105A (en) 1998-01-04
DE69226953T2 (de) 1999-05-12
SG47877A1 (en) 1998-04-17
UA41254C2 (uk) 2001-09-17
NO934800L (no) 1993-12-23
PL169392B1 (pl) 1996-07-31
FI935842A (fi) 1993-12-23
IL102322A0 (en) 1993-01-14
AU652842B2 (en) 1994-09-08
EP0591280B1 (de) 1998-09-09
CZ282083B6 (cs) 1997-05-14
MA22563A1 (fr) 1992-12-31
JPH06508827A (ja) 1994-10-06
NO304774B1 (no) 1999-02-15
US5637611A (en) 1997-06-10
SK280906B6 (sk) 2000-09-12
BR1100460A (pt) 2000-07-18
AP9200403A0 (en) 1992-07-31
AP344A (en) 1994-07-05
AU1977592A (en) 1993-01-25
HU218907B (hu) 2000-12-28
SK280907B6 (sk) 2000-09-12
NZ243288A (en) 1994-09-27
JP3261502B2 (ja) 2002-03-04
HUT68961A (en) 1995-08-28
LU90939I2 (fr) 2002-09-24
PT100620B (pt) 1999-01-29
DK0591280T3 (da) 1999-02-15
SK131993A3 (en) 1994-06-08
BR9206237A (pt) 1995-04-11
CZ150596A3 (en) 1997-05-14
EP0591280A1 (de) 1994-04-13
ATE170746T1 (de) 1998-09-15

Similar Documents

Publication Publication Date Title
DE10299042I1 (de) Verwendung von tetrahydrocarbazolderivaten als 5ht1-Rezeptoragonisten
DE69127791D1 (de) Diazabicyclononyl-Derivate als 5-HT3 Rezeptor Antagonisten
KR950700906A (ko) 5-ht1 작동약으로서의 인돌 유도체(indole derivatives as 5-ht1 agonists)
ATE180785T1 (de) Kondensierte indol-derivate als 5-ht4-rezeptor- antagonisten
DE69431880D1 (de) Verwendung von (2-imidazolin-2-yl-amino) quinoxalinderivaten
ATE222492T1 (de) Verwendung von indolderivaten als 5ht1-agonisten
DE69605430D1 (de) Chinolin-2-on derivate als serotonin antagonisten
DE69401823D1 (de) Indolin derivate als 5ht2c antagonisten
DE69220382D1 (de) Verwendung von Peptidderivaten
FI961628A0 (fi) Indolijohdannaisia NMDA-antagonisteina
DE69418045T2 (de) Amidderivate als 5ht1d rezeptor antagonisten
ATE210659T1 (de) Indolalkylderivate von benzodioxanmenthylamin als 5-ht1a rezeptor liganden
FI962969A (fi) Indolijohdannaisia 5-HT1:n agonisteina
ITMI922661A0 (it) Derivati eterociclici
FI923163A (fi) Foerfarande foer taetning av fogar i byggnader
DE69320653T2 (de) Tetrahydrocarbazolderivate als 5-ht1-ähnliche agonisten
DE58903912D1 (de) Verwendung von 2-substituierten ethansulfonverbindungen als galvanotechnische hilfsstoffe.
DE3888727T2 (de) Verwendung von Äthylamin-Derivaten als antihypertensive Wirkstoffe.
DE69024524T2 (de) Substituierte Tetrahydroindanderivate und ihre Verwendung als Zwischenprodukte
FI943119A (fi) Heterosyklisellä renkaalla substituoituja bentsyyliamiinijohdannaisia retrovirusvastaisina yhdisteinä
DE69222983D1 (de) Heterocyclische Derivate
DE69028985T2 (de) Halophenyl-substituierte heterozyklische derivate